Alnylam Pharmaceuticals
ALNY
#541
Rank
NZ$73.21 B
Marketcap
NZ$552.02
Share price
-0.40%
Change (1 day)
15.93%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2025 (TTM): NZ$0.99 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are NZ$3.71 Billion. , an increase over its 2024 earnings that were of -NZ$0.42 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2025

Annual earnings

Year Earnings Change
2025 NZ$1.00 B-344.47%
2024 -NZ$0.42 Billion-24.59%
2023 -NZ$0.55 Billion-67.84%
2022 -NZ$1.7 Billion36.93%
2021 -NZ$1.24 Billion-8.04%
2020 -NZ$1.35 Billion-15.66%
2019 -NZ$1.6 Billion12.23%
2018 -NZ$1.43 Billion62.91%
2017 -NZ$0.88 Billion17.78%
2016 -NZ$0.75 Billion43.44%
2015 -NZ$0.52 Billion60.69%
2014 -NZ$0.33 Billion98.2%
2013 -NZ$0.17 Billion
2011 -NZ$95.74 Million27.48%
2010 -NZ$75.1 Million-10.92%
2009 -NZ$84.31 Million95.77%
2008 -NZ$43.07 Million
2006 -NZ$68.99 Million-9.13%
2005 -NZ$75.92 Million34.74%
2004 -NZ$56.35 Million36.79%
2003 -NZ$41.2 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
NZ$28.55 B 2,739.98%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
NZ$13.44 B 1,237.20%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
NZ$9.13 B 808.46%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-NZ$0.45 Billion-143.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-NZ$82.84 Million-108.24%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-NZ$0.28 Billion-127.70%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
NZ$3.75 B 273.75%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
NZ$0.60 B-40.06%๐Ÿ‡บ๐Ÿ‡ธ USA